The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EH | Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors | |
| 5 | L01EH03 |
| Active Ingredient | Description | |
|---|---|---|
| Tucatinib |
Tucatinib is a tyrosine kinase inhibitor of HER2. It is used in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| TUKYSA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| TUKYSA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
